Bioventus stock rises ~10% on signing deal to sell Wound business
Bioventus stock rises ~10% on signing deal to sell Wound business
Bioventus to acquire CartiHeal after FDA approval of Agili-C implant
Bioventus stockholders approve Misonix acquisition
Bioventus provides Q2 prelim net sales, updates FY guidance; acquires Misonix for $518M
465.83MUSD
See which Billionaires own this investment
Type
Common Stock
Exchange
NASDAQ
Currency Code
USD
Currency Name
US Dollar
Country Name
USA
Country ISO
US
ISIN
US09075A1088
CUSIP
09075A108
Sector
Healthcare
Industry
Medical Devices
Fiscal Year End
December
IPO date
-
Updated At
-
PE Ratio
-
PEG Ratio
2.14
Book Value
2.24
Dividend Share
-
Dividend Yield
-
Earnings Share
-0.48
Wall Street Target Price
12.33
EPS Estimate Current Year
0.71
EPS Estimate Next Year
0.89
EPS Estimate Current Quarter
0.0228
EPS Estimate Next Quarter
0.2123
Most Recent Quarter
-
Revenue TTM
567,699,008
Gross Profit TTM
382,902,016
EBITDA
58,809,000
Profit Margin
-5.51%
Return On Assets TTM
3.33%
Return On Equity TTM
-20.24%
Revenue Per Share TTM
8.706
Qtly Revenue Growth YOY
-4.30%
Diluted Eps TTM
-0.48
Qtly Earnings Growth YOY
0.00%
Trailing PE
0.00
Forward PE
10
Price Sales TTM
0.8206
Price Book MRQ
3.1444
Enterprise Value Revenue
1
Enterprise Value EBITDA
21
88.19
0.54%134.07
0.31%392.51
0.13%55.08
0.00%233.32
-1.78%297.76
-1.09%27.21
-0.96%103.50
-0.25%76.69
-0.13%82.89
-0.04%